Estonya - Estonca - Ravimiamet

norameda uab - dimetüülfumaraat - gastroresistentne kõvakapsel - 240mg 56tk

Estonya - Estonca - Ravimiamet

teva gmbh - dimetüülfumaraat - gastroresistentne kõvakapsel - 120mg 100tk; 120mg 14tk

Estonya - Estonca - Ravimiamet

teva gmbh - dimetüülfumaraat - gastroresistentne kõvakapsel - 240mg 168tk

Estonya - Estonca - Ravimiamet

sandoz pharmaceuticals d.d. - dimetüülfumaraat - gastroresistentne kõvakapsel - 120mg 14tk

Estonya - Estonca - Ravimiamet

sandoz pharmaceuticals d.d. - dimetüülfumaraat - gastroresistentne kõvakapsel - 240mg 196tk; 240mg 56tk; 240mg 100tk; 240mg 168tk

Avrupa Birliği - Estonca - EMA (European Medicines Agency)

biogen netherlands b.v. - natalisumab - hulgiskleroos - selektiivsed immunosupressandid - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 ja 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Avrupa Birliği - Estonca - EMA (European Medicines Agency)

sandoz gmbh - natalisumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosupressandid - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 ja 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

Estonya - Estonca - Ravimiamet

accord healthcare b.v. - mitoksantroon - infusioonilahuse kontsentraat - 2mg 1ml 15ml 1tk; 2mg 1ml 10ml 1tk; 2mg 1ml 15ml 5tk; 2mg 1ml 5ml 1tk; 2mg 1ml 5ml 5tk; 2mg 1ml 10ml 10tk; 2mg 1ml 15ml 10tk